News stories about Endo International (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.6986466011721 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern’s analysis:
- FINAL DEADLINE ALERT – Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline – January 16, 2018 (finance.yahoo.com)
- Endo International (ENDP) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Endo International (ENDP) Rating Lowered to Sell at BidaskClub (americanbankingnews.com)
- Endo International plc – (ENDP) Sees Large Decrease in Short Interest (americanbankingnews.com)
- Interesting ENDP Put And Call Options For March 2nd (nasdaq.com)
Several analysts recently issued reports on ENDP shares. Zacks Investment Research raised Endo International from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research note on Wednesday, October 11th. Royal Bank of Canada cut their target price on Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. Mizuho reissued a “buy” rating on shares of Endo International in a research note on Friday, November 10th. Leerink Swann started coverage on Endo International in a research note on Tuesday, January 2nd. They issued an “outperform” rating and a $12.00 target price on the stock. Finally, Goldman Sachs Group started coverage on Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 target price on the stock. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Endo International currently has a consensus rating of “Hold” and a consensus target price of $11.27.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.06. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm had revenue of $786.90 million during the quarter, compared to analyst estimates of $794.93 million. During the same period last year, the business earned $1.01 earnings per share. The business’s revenue was down 11.0% on a year-over-year basis. equities research analysts anticipate that Endo International will post 3.67 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Endo International (NASDAQ:ENDP) Earns Daily Media Sentiment Score of 0.05” was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-endo-international-endp-stock-price/1820226.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.